CAR T细胞治疗显示,通过清除有害的白喉细胞,有望扭转小鼠和早期人类细胞与年龄有关的肠道下降趋势。 CAR T-cell therapy shows promise in reversing age-related gut decline in mice and early human cells by clearing harmful senescent cells.

最初针对癌症的CAR T细胞疗法,通过针对随着年龄增长的有害的白种细胞,可以帮助老化的肠道愈合。 CAR T-cell therapy, originally for cancer, may help aging intestines heal by targeting harmful senescent cells that build up with age. 在小鼠体内,这种治疗提高了肠道再生能力,减少了炎症,增加了营养吸收,并避免了辐射损害,其影响长达一年。 In mice, the treatment improved gut regeneration, reduced inflammation, boosted nutrient absorption, and protected against radiation damage, with effects lasting up to a year. 对人体肠细胞的早期检测表明,类似的好处是可能的,为治疗与年龄有关的肠胃衰减和癌症治疗的损害提供了可能性。 Early tests on human intestinal cells suggest similar benefits may be possible, offering potential for treating age-related gut decline and damage from cancer therapy.